Assessment of individual fracture risk: FRAX and beyond

被引:68
作者
Van Den Bergh J.P.W. [1 ,2 ]
Van Geel T.A.C.M. [3 ]
Lems W.F. [4 ]
Geusens P.P. [5 ,6 ]
机构
[1] Department of Internal Medicine, VieCuri Medical Centre Noord-Limburg, Venlo 5900 BX
[2] Faculty of Health Medicine and Life Science, Department of Internal Medicine, Maastricht University/Nutrim, Maastricht 6200 MD
[3] Faculty of Health Medicine and Life Science, Department of General Practice, Maastricht University/Caphri, Maastricht 6200 MD
[4] Department of Rheumatology, VU Medical Centre, Amsterdam 1007 MB
[5] Faculty of Health Medicine and Life Science, Department of Internal Medicine, Maastricht University/Caphri, Maastricht 6200 MD
[6] Biomedical Research Center, University Hasselt, Hasselt
关键词
Fractures; FRAX; Garvan; Osteoporosis; Risk factors; Timing of fractures;
D O I
10.1007/s11914-010-0022-3
中图分类号
学科分类号
摘要
The World Health Organization fracture risk assessment tool (FRAX) and the Garvan fracture risk calculator are both widely available tools for individualized fracture risk prediction in daily practice. The FRAX model is implemented in several guidelines and most widely used at present. However, clinicians should take into account the differences between the models, especially with regard to the effect of the number of falls, number and clustering of previous fractures, and the number of clinical risk factors on the outcome of predicted fracture risk. Further development will be needed for optimal integration of bone- and fall-related risks, clustering of fractures, and dosing of risk factors to validate the models in different populations and to validate the ability to select patients who will achieve fracture risk reduction with anti-osteoporosis therapy. FRAX may be used as the primary model, and in patients with recurrent fractures and falls the use of the Garvan model may be of additional value. © 2010 The Author(s).
引用
收藏
页码:131 / 137
页数:6
相关论文
共 50 条
[1]
Kanis J.A., On Behalf of the World Health Organization Scientific Group: Assessment of Osteoporosis at the Primary Health-Care Level. Technical Report. University of Sheffield, UK: WHO Collaborating Centre
[2]
2008.
[3]
Holroyd C., Cooper C., Dennison E., Epidemiology of osteoporosis, Best Pract Res Clin Endocrinol Metab, 22, pp. 671-685, (2008)
[4]
Van Staa T.P., Dennison E.M., Leufkens H.G., Cooper C., Epidemiology of fractures in England and Wales, Bone, 29, pp. 517-522, (2001)
[5]
Kanis J.A., McCloskey E.V., Johansson H., Et al., A reference standard for the description of osteoporosis, Bone, 42, pp. 467-475, (2008)
[6]
Marshall D., Johnell O., Wedel H., Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, BMJ, 312, pp. 1254-1259, (1996)
[7]
Cummings S.R., Melton L.J., Epidemiology and outcomes of osteoporotic fractures, Lancet, 359, pp. 1761-1767, (2002)
[8]
Geusens P., Strategies for treatment to prevent fragility fractures in postmenopausal women, Best Pract Res Clin Rheumatol, 23, pp. 727-740, (2009)
[9]
Siris E.S., Chen Y.T., Abbott T.A., Et al., Bone mineral density thresholds for pharmacological intervention to prevent fractures, Arch Intern Med, 164, pp. 1108-1112, (2004)
[10]
Kanis J.A., Diagnosis of osteoporosis and assessment of fracture risk, Lancet, 359, pp. 1929-1936, (2002)